Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEBVivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children.
Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEB2 days ago · Designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17, this Vivos device is intended for those diagnosed with snoring and/or OSA who ...
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for …
WEBNov 29, 2023 · The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children.
FDA Clears First Oral Appliance for Severe Sleep Apnea
WEBDec 19, 2023 · For the first time, the Food and Drug Administration (FDA) cleared oral devices that treat severe obstructive sleep apnea (OSA). These devices offer an alternative to more common sleep apnea treatments, like continuous positive airway pressure (CPAP) therapy and surgery.
FDA Clears Vivos CARE Appliance for Severe Obstructive Sleep Apnea
WEBDec 5, 2023 · Recently, the FDA granted 510 (k) clearance to Vivos Therapeutics for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances as a treatment option for patients with severe cases of obstructive sleep apnea (OSA).
Vivos Therapeutics Gets FDA 510(k) Clearance To Treat Pediatric Sleep …
WEB2 days ago · Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring GlobeNewswire 1h Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M
FDA clears Vivos oral appliance for severe obstructive sleep apnea
WEBOn Nov. 29, 2023, Vivos Therapeutics announced it received FDA 510(k) clearance for its line of Complete Airway Repositioning and/or Expansion (CARE) oral appliances for the treatment of severe obstructive sleep apnea (OSA).
US FDA clears Vivos Therapeutics' oral device for sleep apnea
WEBNov 29, 2023 · Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally in the company's shares before the...
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship …
WEBJan 4, 2023 · The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children.
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea ...
WEB2 days ago · On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA ...